The game has changed in biotech.
Continued macroeconomic uncertainty has far reaching implications for the biopharma ecosystem. Access to capital remains low across the industry, and a successful deal with large pharma has become less likely for many. Companies who earlier would have been sellers, may now be progressing development through registrational studies—or all the way through to market. Stated another way, biotechs can no longer operate toward the single goal of being acquired by, or of licensing their assets to, large pharma—accordingly, players may need to develop products further than in the past, and therefore strategic pathway optionality needs to be weaved into and maintained throughout product and corporate development. With these new challenges come multifold new opportunities for value creation.
In this webinar, we discuss strategic and operational implications for the biotech C-suite and share perspectives on how companies can succeed in an increasingly competitive environment.